/ERYP
ERYP Stock - ERYTECH Pharma S.A.
Healthcare|BiotechnologyNASDAQ
$0.78+1.30%
+$0.01 (+1.30%) • Jun 28
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.43
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.35
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.86
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ERYP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.77 – $0.79
TARGET (TP)$0.90
STOP LOSS$0.72
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.13
52W High$1.47
52W Low$0.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $3.36M | $4.14M |
| Gross Profit | N/A | N/A | $-57,580,000 | $-48,829,000 | $-29,330,000 |
| Gross Margin | N/A | N/A | N/A | -1451.5% | -708.8% |
| Operating Income | $-2,796,000 | $-56,515,000 | $-68,832,000 | $5.28M | $4.45M |
| Net Income | $-228,000 | $-53,797,000 | $-73,300,000 | $-62,659,000 | $-38,224,000 |
| Net Margin | N/A | N/A | N/A | -1862.6% | -923.7% |
| EPS | $-0.01 | $-2.27 | $-3.99 | $-3.49 | $-2.13 |
Company Overview
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ERYPBeat Rate
23%
Last 13 quarters
Avg Surprise
-28.8%
EPS vs Estimate
Beats / Misses
3/10
Last 12 quarters
Latest EPS
$0.21
Q4 2022
EPS Surprise History
Q3 21
+9.7%
$-0.65vs$-0.72
Q3 21
-62.7%
$-0.88vs$-0.54
Q4 21
-18.4%
$-0.70vs$-0.59
Q1 22
+1.2%
$-0.42vs$-0.43
Q2 22
No data
Q3 22
No data
Q3 22
No data
Q4 22
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | Apr 26, 2023 | $-0.19 | — | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.21 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.16 | — | — |
Q3 2022 | Sep 12, 2022 | — | $0.37 | — | — |
Q2 2022 | Apr 27, 2022 | — | $-0.55 | — | — |
Q1 2022 | Mar 14, 2022 | $-0.43 | $-0.42 | +1.2% | ✓ BEAT |
Q4 2021 | Nov 16, 2021 | $-0.59 | $-0.70 | -18.4% | ✗ MISS |
Q3 2021 | Sep 20, 2021 | $-0.54 | $-0.88 | -62.7% | ✗ MISS |
Q3 2021 | Jul 8, 2021 | $-0.72 | $-0.65 | +9.7% | ✓ BEAT |
Q1 2021 | Mar 8, 2021 | $-0.90 | $-1.35 | -50.0% | ✗ MISS |
Q4 2020 | Nov 5, 2020 | $-0.90 | $-1.22 | -35.2% | ✗ MISS |
Q2 2020 | Jun 30, 2020 | — | $-1.10 | — | — |
Q2 2020 | May 6, 2020 | $-0.77 | $-1.07 | -38.6% | ✗ MISS |
Q1 2020 | Mar 18, 2020 | $-0.86 | $-1.21 | -40.7% | ✗ MISS |
Q4 2019 | Nov 7, 2019 | $-0.78 | $-0.85 | -9.2% | ✗ MISS |
Q3 2019 | Sep 27, 2019 | $-0.81 | $-1.12 | -37.7% | ✗ MISS |
Q2 2019 | May 6, 2019 | $-0.38 | $-0.73 | -92.2% | ✗ MISS |
Q1 2019 | Mar 11, 2019 | $-0.60 | $-0.45 | +25.0% | ✓ BEAT |
Q4 2018 | Nov 12, 2018 | $-0.55 | $-0.69 | -26.2% | ✗ MISS |
Q2 2018 | May 14, 2018 | $-0.50 | — | — | — |
Latest News
Loading news...
Frequently Asked Questions about ERYP
What is ERYP's current stock price?
ERYTECH Pharma S.A. (ERYP) is currently trading at $0.78 per share. The stock has moved +1.30% today.
What is the analyst price target for ERYP?
No analyst price targets are currently available for this stock.
What sector is ERYTECH Pharma S.A. in?
ERYTECH Pharma S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ERYP's market cap?
ERYTECH Pharma S.A. has a market capitalization of $0.05 billion, making it a small-cap company.
Does ERYP pay dividends?
No, ERYTECH Pharma S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALVR
AlloVir, Inc.
$9.81
Mkt Cap: $0.0B
BLUE
bluebird bio, Inc.
$4.97
Mkt Cap: $0.0B
CERC
Cerecor Inc.
$2.93
Mkt Cap: $0.0B
GRNA
GreenLight Biosciences Holdings
$0.30
Mkt Cap: $0.0B
KRON
Kronos Bio, Inc.
$0.88
Mkt Cap: $0.1B
MGTA
Magenta Therapeutics, Inc.
$0.70
Mkt Cap: $0.0B
PSTI
Pluristem Therapeutics Inc.
$1.00
Mkt Cap: $0.0B
RENB
Lunai Bioworks Inc.
$1.42
Mkt Cap: $0.0B
RNTX
Rein Therapeutics Inc.
$1.42
Mkt Cap: $0.0B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
Explore stocks similar to ERYP for comparison